Floatz logo

Eptinezumab

Migraine With Aura

University of Florencemonoclonal_antibodyUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Migraine With Aura cohort.

Asset / SponsorPhaseRating
Topiramate
Tongji Hospital
Phase 4BBB
Apsolol
Norwegian University of Science and Technology
Phase 3BB
DHE
Satsuma Pharmaceuticals, Inc.
Phase 3BB
Rimegepant
University of South Florida
Phase 4BB
DFN-11 (SUMATRIPTAN INJECTION)
University of Aarhus
Phase 3BB

View all 48 →

Same molecule, other indications

Eptinezumab is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
79 / 100
View asset →
tinnitusActive
B
Indicative · Phase 4
62 / 100
View asset →
migraine without auraActive
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →